Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

65992 1510824253HCLSReviewUkraineNovember2017.pdf
Energy Boardroom

Allergan cautions against exchange as Valeant gets down to the 'facts'

23.06.2014 / Fierce Pharma

Allergan's board has already rejected Valeant's $53 billion buyout bid, prompting the wannabe-acquirer to take the proposal directly to shareholders. Unsurprisingly enough, Allergan's board doesn't like that too much, either. And if you ask Valeant, it's twisting the facts to get shareholders on its side.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: